Thrombosis Risk in Multiple Myeloma Patients
Author Information
Author(s): Hugo Jiménez-Zepeda, Jeanet Domínguez-Martínez
Primary Institution: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Hypothesis
Is there an association between thalidomide plus chemotherapy and DVT development in newly diagnosed multiple myeloma patients?
Conclusion
APC-R may be related to myeloma status and increases the risk of thrombotic complications in these patients.
Supporting Evidence
- DVT developed in 8 out of 50 patients (16%).
- Four out of six patients with APC-R developed DVT (66%).
- Patients receiving thalidomide plus dexamethasone had a higher overall response rate compared to those receiving VAD.
Takeaway
Patients with multiple myeloma who take thalidomide and chemotherapy are more likely to develop blood clots.
Methodology
This was a prospective, descriptive, longitudinal, and observational study evaluating coagulation tests in newly diagnosed multiple myeloma patients.
Potential Biases
Potential biases may arise from the observational nature of the study and the specific patient population.
Limitations
The study was limited to a specific cohort of patients and may not be generalizable to all multiple myeloma patients.
Participant Demographics
The cohort included 27 males (54%) and 23 females (46%), aged 45-83 years (mean 63).
Statistical Information
P-Value
0.007
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website